Uncategorized-EN
Study Results
The following table lists the results of some of the many clinical trials available worldwide for sarcoma, GIST or desmoid patients. For more information about some of the ongoing trials, click here. No Trial Name Agents Phase Status Results Sponsor 1 Study 62005 Imatinib in twodifferent dosings III Closed Results Study 62005 EORTC Note: The…
Read MoreEarly Involvement
Clinical studies are an essential step in the development of novel treatment methods for cancer and other diseases. They show researchers what works for the welfare of patients and what does not. In addition to safety and effectiveness they also determine whether the side effects of a new treatment are acceptable and, increasingly, what quality…
Read MorePatients & Studies
Research Networks
The EORTC Soft Tissue and Bone Sarcoma Group (STBSG) The objectives of the STBSG were to develop, stimulate and co-ordinate studies on all aspects of the treatment of soft tissue sarcomas (STS) as well as to organise congresses, symposia and conferences to promote these studies. Today the STBSG has members from 56 institutions from 14…
Read MoreSubmitted Abstracts
Setting the international research agenda for sarcoma together with patients and carers: first results of the Sarcoma Patient EuroNet (SPAEN) priority setting partnershipPublished in ESMO Open, June 2022 Research in sarcomas has historically been the domain of scientists and clinicians attempting to understand the disease to develop effective treatments. This traditional approach of placing scientific…
Read MorePolicy Checklist
There are currently parallel initiatives on the way of developing European policy recommendations for the care of sarcoma patients. The âSarcoma Policy Checklistâ aims to help drive meaningful policy changes for sarcoma patients across Europe. It was launched February 8th, 2017 and has now been published in BMC Cancer. It can be accessed here or…
Read MorePosition Papers
The SPAEN Clinical Sarcoma Research Paper on “The challenge of sarcomas: the patient advocacy group perspective” has been written by Roger Wilson, SPAEN honorary president and a sarcoma patient advocate for more than 20 years. The patient advocacy agenda covers every aspect of cancer treatment and care. This inevitably means that this review covers almost…
Read MoreCancer Profiles
Soon to come
Read MoreEwing Sarcomas
Introduction Ewing sarcoma is a rare and highly malignant tumor. About 3 in one million patients under the age of 15 and only 2,4 in one million above the age of 15 are affected by Ewing sarcoma in the Caucasian population; in other ethnicities the tumor is even less frequent. Ewing sarcoma is a disease…
Read MoreLeiomyosarcoma
Introduction Leiomyosarcoma (LMS) is one of the most common subtypes of soft tissue sarcoma (STS) and accounts for approximately 24%, LMS start from cells in a type of muscle tissue called smooth muscle or involuntary muscles – the brain has no conscious controlover them. They can be found in the walls of muscular organs like…
Read More